Skip to main content

Peer Review reports

From: Cost-effectiveness of immune checkpoint inhibition and targeted treatment in combination as adjuvant treatment of patient with BRAF-mutant advanced melanoma

Original Submission
20 Jun 2022 Submitted Original manuscript
24 Sep 2022 Reviewed Reviewer Report
11 Oct 2022 Reviewed Reviewer Report
24 Nov 2022 Author responded Author comments - Sini Li
Resubmission - Version 2
24 Nov 2022 Submitted Manuscript version 2
12 Dec 2022 Reviewed Reviewer Report
16 Dec 2022 Reviewed Reviewer Report
25 Dec 2022 Author responded Author comments - Sini Li
Resubmission - Version 3
25 Dec 2022 Submitted Manuscript version 3
Publishing
10 Jan 2023 Editorially accepted
18 Jan 2023 Article published 10.1186/s12913-023-09058-7

You can find further information about peer review here.

Back to article page